Biological Mimetics

Biological Mimetics, Inc. (BMI) is a Frederick, Maryland-based biomedical company founded in 1996 that integrates biology and engineering to develop solutions for emerging and resistant infectious diseases. Its core technology platforms include Immune Refocusing Technology (IRT), which uses bioinformatic analysis to direct the immune system toward conserved, less antigenic sites on pathogens, and an ultra-inactivation vaccine platform that utilizes a manganese-decapeptide-phosphate (MDP) system combined with UVC irradiation for cost-effective vaccine production. Additionally, the company has developed the FAST diagnostic tool, a multi-chambered, instrument-free system designed for sensitive, CRISPR-based nucleic acid detection in resource-limited environments.

BMI collaborates extensively with academic, military, and governmental organizations to advance its vaccine and diagnostic candidates toward commercialization and regulatory approval. These efforts address a wide range of global health challenges, including viral pathogens like Influenza and COVID-19, as well as antibiotic-resistant bacteria and parasitic diseases. By providing tools that are reproducible, easy to manufacture, and deployable in the field, BMI aims to improve public health outcomes in both low-income regions and developed medical settings. The company sustains its development pipeline through research grants and strategic partnerships with entities such as the NIH and the Department of Defense.